A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01143714
Recruitment Status : Completed
First Posted : June 14, 2010
Results First Posted : May 3, 2013
Last Update Posted : May 6, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to assess the effect of four weeks of treatment with Santyl Ointment, compared to White Petrolatum, on the change from baseline in wound area of diabetic foot ulcers over four weeks, and on the proportion of subjects achieving complete wound closure within 12 weeks from initiation of treatment.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcers Drug: Santyl Other: White Petrolatum Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Vehicle-Controlled Study to Determine the Effect of Four Weeks of Debridement With Collagenase Santyl Ointment (Santyl) on the Healing of Diabetic Foot Ulcers
Study Start Date : June 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Petrolatum

Arm Intervention/treatment
Active Comparator: A Drug: Santyl
Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.

Placebo Comparator: B Other: White Petrolatum
Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.

Primary Outcome Measures :
  1. Change in Wound Area [ Time Frame: 4 Weeks ]
    The primary efficacy endpoint was the percent change in wound area from baseline to completion of the 4-week treatment phase and the 8-week follow-up period

Secondary Outcome Measures :
  1. Number of Sharp Debridements Performed During the 4-week Treatment Phase and the 8-week Follow-up Period (12 Weeks Total) [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The informed consent document Photography Release must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting the screening visit. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.
  • Age 18 years and older. Subjects may be of either sex and of any race or skin type.
  • Women of child-bearing potential (those who are not premenarchal, not surgically sterilized [hysterectomy or bilateral oophorectomy], or not post-menopausal) may participate in the study if they meet all of the following conditions:

    • they are not breast feeding
    • undertake an HCG serum pregnancy test, which must be negative
    • they do not intend to become pregnant during the study
    • they are using adequate birth control methods and they agree to continue using those methods for the duration of the study
  • Post-menopausal is defined as no period in the previous 12 months Adequate birth control methods are defined as: hormonal—topical, oral, implantable or injectable contraceptives; mechanical—spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or, surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use an adequate birth control method as described above for the remainder of the study.

NOTE: Women who have had a bilateral tubal ligation are not considered to have been surgically sterilized and must agree to the conditions as specified above.

  • Willing to make all required study visits and to use the Darco shoe off-loading device and insole.
  • Able to follow instructions, particularly regarding the application of test articles and dressings at home. Able to apply the test article, or has a caregiver available to apply the test article according to the protocol.
  • Have a diabetic foot ulcer, Wagner Grades† 1 or 2, on the plantar surface of the foot.
  • Target ulcer present for at least 28 days, but no longer than 18 months, and has failed to close by ≥ 40% during the first 4 weeks of therapy administered during the past 4 to 8 weeks.
  • Target ulcer area between 2 and 15 cm², post debridement, if required. 9- Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1; if the ABI is greater than 1.1, then a toe pressure of > 30 mmHg OR a TcPO2 ≥ 40 mmHg; either secondary measure is acceptable, but if both are obtained, each must meet its respective cutoff.
  • 10. Reasonable control of blood glucose, as evidenced by a serum HbA1C ≤ 12% at screening.
  • 11.Acceptable state of health and nutrition as evidenced by a serum pre-albumin level ≥ 15 mg/dL (0.15 g/L) and serum albumin ≥ 2.0 g/dL (20 g/L) at screening.
  • 12. Hematology values in the following ranges: WBC ≥ 3.0x109/L Hgb ≥ 10.0 g/dL Neutrophils ≥ 1.5x109/L Platelets ≥ 75 x109/L Normal blood smear
  • Blood chemistry values and urinalysis in the following ranges (Healthpoint Ranges):

Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) Alkaline phosphatase ≤ 2.5 times the ULN Alanine transaminase (ALT) ≤ 2.5 times the ULN Aspartate transaminase (AST) ≤ 2.5 times the ULN Serum creatinine ≤ 1.5 times the ULN Urinalysis: WBC < 4/HPF; RBC < 4/HPF

Exclusion Criteria:

  • Contraindications or known hypersensitivity to the test articles or their components.
  • Therapy with another investigational agent within 30 days, lower extremity angioplasty within 4 weeks, untreated osteomyelitis, or chemotherapy or radiation therapy within 5 years prior to screening.
  • Prior therapy of the target wound with Santyl.
  • Current therapy with systemic antibiotics to treat a foot ulcer, or prescription topical antibiotics on the target ulcer.
  • Target ulcer located over the heel (talus, distal calcaneous, navicular, or cuboid).
  • Fracture of bones in the target ulcer foot occurring within the past 3 months.
  • Cellulitis or abscess of the target ulcer foot.
  • A positive result from the screening Quantitative Bacteriology (Qbac) biopsy. A wound will be considered infected if the laboratory findings reveal ≥ 106 colony forming units (cfu) per gram of tissue or > 1 beta-hemolytic Streptococcus per gram of tissue.
  • Target ulcer tunneling, per probing.
  • More than three DFU on the target foot. The target ulcer must be at least 2 cm from another ulcer.
  • Concomitant severe burn, immunodeficiency disorder, hematologic disorder, or malignancy (other than non-melanoma skin cancer) beyond the in situ stage.
  • Abnormal laboratory values that, in the opinion of the Principal Investigator, place the subject at risk for the study.
  • Positive serum HCG pregnancy test.
  • The Medical Monitor may declare any subject ineligible for a valid procedural or medical reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01143714

United States, California
Olive View - UCLA Medical Center
Sylmar, California, United States, 91342
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60154
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118-2309
United States, Pennsylvania
The Foot and Ankle Institute of Western Pennsylvania
Pittsburgh, Pennsylvania, United States, 15224
Center for Advanced Wound Care
Wyomissing, Pennsylvania, United States, 19610
United States, Texas
Complete Family Foot Care
McAllen, Texas, United States, 98501
Sponsors and Collaborators
Study Chair: Herbert B Slade, MD Healthpoint

Responsible Party: Healthpoint Identifier: NCT01143714     History of Changes
Other Study ID Numbers: 017-101-09-024
First Posted: June 14, 2010    Key Record Dates
Results First Posted: May 3, 2013
Last Update Posted: May 6, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases
Dermatologic Agents